Pharma + healthcare


Ab Dilli door nahi: Ranjan Pai is paying a hefty price for Medanta to break his northern jinx

After multiple unsuccessful attempts to break into the critical north Indian market, Manipal is placing a seemingly expensive bet on Medanta. Manipal’s investors are nearing their exit windows, increasing the pressure on the company to deliver returns. Other prominent hospital chains, including NH and HCG, have taken the same route in an industry struggling for growth.



[[/message]] [[#message]]